Effects of Acute, Rapid Lowering of Low Density Lipoprotein (LDL) Cholesterol with Alirocumab in Patients with STEMI Undergoing Primary PCI
Evaluating the effects of acute treatment with a PCSK9 inhibitor (alirocumab) versus placebo on low-density lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary PCI. The hypothesis is that, in patients with STEMI undergoing primary PCI, rapid lowering of LDL cholesterol with a PCSK9 Inhibitor (alirocumab) initiated in the acute setting pre-PCI, will favourably affect LDL cholesterol concentrations compared with placebo.
A randomized, double-blind, placebo controlled parallel group clinical trial
To determine the effect of acute, rapid lowering of LDL cholesterol with alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI.
Shamir Mehta, Eva Lonn, Gui Paré, Matthew McQueen